NBIX

Q: What is the price of Neurocrine (NBIX) today?

The current price of Neurocrine (NBIX) is $ 130.81, representing a 37.85% gain over the past year. The stock began the year trading around $ 141.83 and is currently priced at $ 130.81. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

Q: When does Neurocrine (NBIX) pay dividends?

Neurocrine (NBIX) did not pay dividends over the past year.

Q: Is Neurocrine (NBIX) a good investment?

Neurocrine (NBIX) is currently trading at $ 130.81 with a P/E ratio of 27.53%. This represents a 4,841% premium compared to its historical average P/E. Over the past year, the stock has gained 37.85 and paid $ 0.00 in dividends, resulting in a dividend yield of 0.00%. The total shareholder return over the same period was 37.85%.Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

Neurocrine Biosciences Inc.

Price

$ 130.81

return (12m)

37.85%

p/e

27.53

p/bv

4.05

DIVIDEND YIELD

0.00%

NBIX price

NBIX

If you had invested

years ago

7 days

30 days

6 months

YTD

1 year

5 years

10 years

ago, you would now have *

ago, you would now have:

*The figure considers the reinvestment of dividends.

Return on Investment NBIX

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.79%

3 months

-3.34%

1 year

37.85%

2 years

-2.86%

5 years

37.69%

10 years

180.29%

Fundamentals NBIX

review the fundamentals of Neurocrine shares

P/E

27.53

Sector: -3.96 Industry: -3.96

P/S (PSR)

4.61

Sector: -3.88 Industry: -3.88

P/BV

4.05

Sector: 1.87 Industry: 1.87

DIVIDEND YIELD (DY)

0.00%

Sector: - Industry: -

ROA

10.33%

Sector: -61.39% Industry: -61.39%

ROE

14.71%

Sector: -60.71% Industry: -60.71%

ROIC

20.39%

Sector: -1,194.93% Industry: -1,194.93%

NET MARGIN

16.73%

Sector: -39.39% Industry: -39.39%

GROSS MARGIN

98.18%

Sector: 38.09% Industry: 38.09%

OPERATING MARGIN

22.25%

Sector: -39.58% Industry: -39.58%

EV/EBITDA

19.76

Sector: -3.80 Industry: -3.80

EV/EBIT

20.70

Sector: -4.02 Industry: -4.02

PRICE-TO-ASSETS

2.84

Sector: 1.38 Industry: 1.38

BVPS

32.53

Sector: 1.89 Industry: 1.89

EPS

4.79

Sector: -2.05 Industry: -2.05

EQUITY-TO-ASSETS RATIO

0.70

Sector: 0.42 Industry: 0.42

LIABILITIES / ASSETS

0.30

Sector: 0.39 Industry: 0.39

CAGR REVENUE 5 YEARS

20.34%

Sector: - Industry: -

CAGR PROFIT 5 YEARS

39.81%

Sector: - Industry: -

FAIR VALUE OF Neurocrine ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$ 130.81

Fair Value

$ 0.00

Upside/Downside Return potential.

-54.74%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals NBIX

DRAG THE FRAME TO SEE MORE DATA

Stock Comparison Tool

DRAG THE FRAME TO SEE MORE DATA

	p/e	p/bv	ROE	dy	market cap	net margin
JNJ	21.88	7.40	33.81%	2.14%	$ 586.59 B	28.46%
PFE	20.06	1.67	8.35%	6.28%	$ 155.85 B	12.42%
ABBV	89.02	0.00	0.00%	3.12%	$ 376.19 B	6.91%
NVO	10.61	5.46	51.50%	4.98%	$ 166.18 B	33.05%
MRK	16.72	0.00	0.00%	2.70%	$ 305.21 B	28.08%
AZN	31.27	6.56	20.99%	1.55%	$ 319.77 B	17.41%
GILD	20.77	7.81	37.62%	2.24%	$ 176.72 B	28.90%
BMY	16.98	-3.52	-20.72%	4.23%	$ 119.74 B	14.64%
ZTS	19.59	15.72	80.25%	1.70%	$ 52.37 B	28.23%
REGN	17.51	2.52	14.41%	0.47%	$ 78.86 B	31.41%
HALO	24.94	161.91	649.21%	0.00%	$ 7.90 B	22.69%
AMGN	24.97	22.24	89.06%	2.70%	$ 192.51 B	20.98%
MCK	24.84	-1,089.08	-4,383.84%	0.36%	$ 107.82 B	1.09%
VRTX	28.42	6.02	21.18%	0.00%	$ 112.36 B	32.94%
CAH	30.78	-18.95	-61.56%	0.94%	$ 51.16 B	0.68%
HRMY	10.31	1.88	18.24%	0.00%	$ 1.64 B	18.27%
ADMA	16.29	5.01	30.78%	0.00%	$ 2.39 B	28.80%
BIIB	20.21	1.43	7.08%	0.00%	$ 26.12 B	13.07%

Stock vs Indice Comparison Tool

If you had invested (change) 2 years years ago, ago, you would now have

R$ 1.000,00 in PETR4 You would now have R$ 2.294,60

R$ 1.000,00 in LEVE3 You would now have R$ 5.240,60

*The value considers the reinvestment of dividends.

NBIX Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Neurocrine

Neurocrine Biosciences Inc.

Average Investor10 user rating

4.0 (4 people)

United States

34 years

Founded: 1992

1996

Time since IPO - 30 years

845

Employees

Neurocrine Biosciences Inc. (United States) is listed on the Nasdaq and has a market capitalization of $13.17 Billions, with shareholders equity totaling $3.25 Billions.

The company employs approximately 845 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Neurocrine Biosciences Inc. reported $2.86 Billions in revenue, generating net income of $478.60 Millions.

Key financial metrics include a P/E ratio of 27.53, a price-to-book (P/B) ratio of 4.05, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker NBIX.

Market cap

$ 13.17 Billions

Net worth

$ 3.25 Billions

$ 3,253,100,000.00

Assets

$ 4.63 Billions

$ 4,631,500,000.00

Total Shares Outstanding

100.00 Millions

100,000,000

Average Daily Trading Volume

$ 1.11 Million

$ 1,111,340.94

Sector

Health Care

Industry

Biotechnology

NBIX

NBIX revenue and profits

Financial Results NBIX

DRAG THE FRAME TO SEE MORE DATA

NBIX cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more stocks

BFRA - Biofrontera

$ - -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$ 862.96 25,04% (12M)

P/E

24.84

0.36%

ROE

-4,383.84%

P/BV

-1,089.08

CAH - Cardinal Health

$ 214.95 61,92% (12M)

P/E

30.78

0.94%

ROE

-61.56%

P/BV

-18.95

JNJ - Johnson & Johnson

$ 240.16 60,69% (12M)

P/E

21.88

2.14%

ROE

33.81%

P/BV

7.40

PFE - Pfizer

$ 27.11 29,58% (12M)

P/E

20.06

6.28%

ROE

8.35%

P/BV

1.67

ABBV - AbbVie

$ 210.26 23,84% (12M)

P/E

89.02

3.12%

ROE

0.00%

P/BV

0.00

MRK - Merck & Co.

$ 119.96 58,59% (12M)

P/E

16.72

2.70%

ROE

0.00%

P/BV

0.00

AZN - AstraZeneca

$ 204.64 55,33% (12M)

P/E

31.27

1.55%

ROE

20.99%

P/BV

6.56

BFRA - Biofrontera

$ - -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$ 862.96 25,04% (12 M)

P/L

24.84

0.36%

ROE

-4,383.84%

P/VP

-1,089.08

CAH - Cardinal Health

$ 214.95 61,92% (12 M)

P/L

30.78

0.94%

ROE

-61.56%

P/VP

-18.95

JNJ - Johnson & Johnson

$ 240.16 60,69% (12 M)

P/L

21.88

2.14%

ROE

33.81%

P/VP

7.40

PFE - Pfizer

$ 27.11 29,58% (12 M)

P/L

20.06

6.28%

ROE

8.35%

P/VP

1.67

ABBV - AbbVie

$ 210.26 23,84% (12 M)

P/L

89.02

3.12%

ROE

0.00%

P/VP

0.00

MRK - Merck & Co.

$ 119.96 58,59% (12 M)

P/L

16.72

2.70%

ROE

0.00%

P/VP

0.00

AZN - AstraZeneca

$ 204.64 55,33% (12 M)

P/L

31.27

1.55%

ROE

20.99%

P/VP

6.56

Frequently Asked Questions

What is the price of Neurocrine (NBIX) today?

The current price of Neurocrine (NBIX) is $ 130.81, representing a 37.85% gain over the past year. The stock began the year trading around $ 141.83 and is currently priced at $ 130.81. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

When does Neurocrine (NBIX) pay dividends?

Neurocrine (NBIX) did not pay dividends over the past year.

Is Neurocrine (NBIX) a good investment?

Neurocrine (NBIX) is currently trading at $ 130.81 with a P/E ratio of 27.53%. This represents a 4,841% premium compared to its historical average P/E. Over the past year, the stock has gained 37.85 and paid $ 0.00 in dividends, resulting in a dividend yield of 0.00%. The total shareholder return over the same period was 37.85%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Neurocrine (NBIX) stock?

You can buy Neurocrine (NBIX) shares through any brokerage account that provides access to U.S. stock exchanges. After opening and funding your account, simply search for the ticker symbol NBIX and place a buy order. Before investing, consider factors such as your financial goals, risk tolerance, and overall portfolio allocation.

How much would 100 shares of Neurocrine (NBIX) yield today?

Over the past month, Neurocrine (NBIX) has returned 0.79% — 37.85% over the past year, and 37.69% over the past five years, including price appreciation and dividends.

In the last 12 months, the company paid a total of 0.00 per share in dividends, resulting in a dividend yield of 0.00%.

If you were to purchase 100 shares of Neurocrine (NBIX) today at the current price of $ 130.81 your total investment would be $ 13,081.00.

Based on historical performance, the investment would have grown to approximately:

$ 18,032.16 after 1 year
$ 18,011.23 after 5 years
$ 36,664.73 after 10 years

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

NBIX

Neurocrine Biosciences Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment NBIX

review the fundamentals of Neurocrine shares

P/E

P/S (PSR)

P/BV

DIVIDEND YIELD (DY)

ROA

ROE

ROIC

NET MARGIN

GROSS MARGIN

OPERATING MARGIN

EV/EBITDA

EV/EBIT

PRICE-TO-ASSETS

BVPS

EPS

EQUITY-TO-ASSETS RATIO

LIABILITIES / ASSETS

CAGR REVENUE 5 YEARS

CAGR PROFIT 5 YEARS

Graham's Fair Value

If you had invested (change) 2 years years ago, ago, you would now have

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Neurocrine

Neurocrine Biosciences Inc.

United States

34 years

1996

845

PROFIT X PRICE NBIX

Financial Results NBIX

NBIX cash flow

Asset, Revenue and Profit Growth - NBIX

NBIX balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

PFE - Pfizer

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

PFE - Pfizer

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

Frequently Asked Questions